Zydus Cadila receives US FDA approval for Meloxicam

New Delhi, July 20 (UNI) Ahmedabad-based Zydus Cadila Healthcare today said it received an approval from the US Food and Drug Administration to market Meloxicam tablets 7.5 mg and 15 mg, in the US market.

The drug falls in the pain management segment. The branded sales of Meloxicam tablets in the US market in 2005 was pegged at 1.26 billion dollars.

This marks the 16th ANDA approval for the group since the commencement of filing process in FY 2003-04. So far, the group has filed 37 ANDAs and 40 DMFs.

Earlier this month, Zydus Cadila received tentative approval from US FDA to market Pravastatin Sodium tablets in the US market.

UNI CS SBA VC1200